ArticleOncotarget2019

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.

Devika Rao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.